Flamingo Therapeutics
Mark Gidjunis has a strong background in finance and accounting, with experience in various roles at companies such as Flamingo Therapeutics, Dynacure, Optinose, KPMG US, and Heffler, Radetich & Saitta LLP. Mark's responsibilities have included overseeing audits for companies in the pharmaceutical and life sciences industries, determining appropriate accounting treatments for complex transactions, and holding titles such as VP Finance, Corporate Controller, Assistant Controller, and Audit Senior Manager. Mark holds a BS in Accounting from Rutgers University - Camden.
This person is not in any teams
This person is not in any offices
Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.